肿瘤细胞中基因选择性剪接的研究进展  

A progress toward research on alternative splicing of genes in tumorcells

作　　者：周助人[1] 孙开来[1] 

机构地区：[1]中国医科大学基础医学院医学遗传学教研室,沈阳110001

出　　处：《中华医学遗传学杂志》2006年第2期177-180,共4页Chinese Journal of Medical Genetics

基　　金：国家自然科学基金(30571836);863子课题(2002BA711A08-18)~~

摘　　要：选择性剪接是高等真核细胞在转录后水平调控基因表达以及产生蛋白质组多样性的重要机制。选择性剪接过程受多种顺式作用元件和反式作用因子相互作用调节。肿瘤癌基因、抑癌基因、肿瘤转移抑制基因可发生选择性剪接,与肿瘤发生发展关系密切,其蛋白异构体参与基因转录、细胞周期和凋亡等生命过程,对肿瘤生长有一定作用。以选择性剪接蛋白异构体为靶点或干预选择性剪接过程,可望进行肿瘤的分子治疗。Alternative splicing of pre-mRNA is an important mechanism for regulating gene function at the posttranscription level and for producing proteomic diversity in higher eukaryotes. The alternative splicing is regulated by the interaction between diverse cis-acting elements and trans-acting factors. Alternative splicing events of oncogenes, tumor suppressor genes and metastasis suppressor genes are associated with the initiation and development of human neoplasms. The protein isoforms sourced from alternative splicing take part in regulating the gene transcription, cell cycle, apoptosis of cells, and playing a role in tumor growth. It is possible for molecular therapy to target directly isoforms of protein produced by alternative splicing or to interfere with the process of alternative splicing.

关 键 词：选择性剪接 肿瘤 MRNA前体 基因表达 

分 类 号：R73-3[医药卫生—肿瘤]